id,collection,Date,Journal title,Language,MeSH Headings,MeSH qualifiers,Title,Type,dc.date.accessioned,dc.date.available,dc.date.created,dc.identifier.uri,dc.subject.other "56899","10665/26722","1998","WHO drug information 1998 ; 12(4) : 234-242","en","Serotonin Uptake Inhibitors::Serotonin Uptake Inhibitors::600||Fluoxetine::Fluoxetine::600||Paroxetine::Paroxetine::600||Sertraline::Sertraline::600||Piperazines::Piperazines::600||HIV Protease Inhibitors::HIV Protease Inhibitors::600||Cisapride::Cisapride::600||Benzimidazoles::Benzimidazoles::600||Isotretinoin::Isotretinoin::600||Anti-Obesity Agents::Anti-Obesity Agents::600||Antibodies, Monoclonal::Antibodies, Monoclonal::600||Antineoplastic Agents::Antineoplastic Agents::600||Ritonavir::Ritonavir::600||N-Methyl-3,4-methylenedioxyamphetamine::N-Methyl-3,4-methylenedioxyamphetamine::600||Influenza Vaccines::Influenza Vaccines::600||Ritodrine::Ritodrine::600||Flutamide::Flutamide::600||Nicergoline::Nicergoline::600||Histamine H2 Antagonists::Histamine H2 Antagonists::600||Cyclooxygenase Inhibitors::Cyclooxygenase Inhibitors::600||Vaccines, Attenuated::Vaccines, Attenuated::600||Misoprostol::Misoprostol::600||Analgesics::Analgesics::600||Leukotriene Antagonists::Leukotriene Antagonists::600||Flunitrazepam::Flunitrazepam::600||Nicergoline::Nicergoline::600||Catechol O-Methyltransferase::Catechol O-Methyltransferase::600||Drugs, Chinese Herbal::Drugs, Chinese Herbal::600||Legislation, Drug::Legislation, Drug::600||Fraud::Fraud::600||Drug Interactions::Drug Interactions::600||Drug Approval::Drug Approval::600||Drug Evaluation::Drug Evaluation::600||World Health Organization::World Health Organization::600||Australia::Australia::600||Brazil::Brazil::600||European Union::European Union::600||Germany::Germany::600||Japan::Japan::600||Sweden::Sweden::600||Switzerland::Switzerland::600||United Kingdom::United Kingdom::600||United States::United States::600","adverse effects||adverse effects supply and distribution||contraindications adverse effects||administration and dosage supply and distribution||supply and distribution||therapeutic use supply and distribution||contraindications||metabolism||standards||adverse reactions||standards supply and distribution||chemistry||pharmacology||antagonists and inhibitors pharmacology||prevention and control","Regulatory matters","Journal / periodical articles","2012-06-16T17:28:31Z","2012-06-16T17:28:31Z","1998","https://iris.who.int/handle/10665/56067","Pharmaceuticals and Biologicals"